As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and from low- and middle-income countries.

Read Professor Hughes' CML publications of the month: March 2025

Clinical CML papers

• Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review
  Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print)
• Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter?
  Dalgetty M and Cortes JE. Blood, March 2025 (epub ahead of print)
• Imatinib and the dawn of precision cancer medicine
  Druker BJ. Nat Med, March 2025
• Living, not just surviving with CML – quality of life to the front of the line
  Lipton JH and Rea D. Leukemia, March 2025 (epub ahead of print)
• Chronic myeloid leukemia: A review
  Jabbour E and Kantarjian H. JAMA, March 2025 (epub ahead of print)
• Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors
  Rodrigues Moreira P et al. J Oncol Pharm Pract, March 2025 (epub ahead of print)
• Do we need another TKI for chronic myeloid leukemia?
  Hjorth-Hansen H. Lancet Haematol, March 2025
• Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
  Busque L et al. Blood Cancer J, March 2025 – open access publication

Scientific CML papers

• Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission
  Camado MF et al. Clin Exp Med, March 2025 – open access publication
• A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
  Wang J et al. Nat Cancer, March 2025 (epub ahead of print)

Pediatric CML papers

• Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric chronic myeloid leukemia expert panel recommendations
  Millot F et al. Leukemia, March 2025 (epub ahead of print)
• Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Data from a real-world setting
  Suttorp M et al. Br J Haematol, March 2025 (epub ahead of print) – open access publication
• Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era
  Yoshikawa T et al. Int J Hematol, March 2025 (epub ahead of print) – open access publication
• Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response
  Michalowski, MB et al. Case Reports in Oncological Medicine, March 2025 – open access publication

LMIC CML papers

• Management of CML and pregnancy in low- and middle-income countries
  Malhotra N et al. Indian J Hematol Blood Transf, January 2025
• Impact of dasatinib on female reproductive health in Philadelphia-positive leukemia patients
  Kintada S et al. Indian J Hematol Blood Transf, December 2024
  
  

Read Professor Hughes' summaries of key CML publications

This series of paper summaries is an extension of Professor Tim Hughes' 'CML publications of the month' news service.
These summaries, selected and curated by Professor Hughes, will be compiled and provided every three months, offering a comprehensive overview of key CML papers. This approach ensures that clinicians, researchers, and healthcare professionals stay up-to-date with important pivotal studies and emerging trends in CML research.

CML paper summary #4 - April 2025:
High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia
Link to full paper (Blood (2025) 145 (15): 1670–1686)

This study published in Blood explored how natural killer (NK) cells, a type of immune cell known for targeting cancer cells, could be more effective against chronic myeloid leukemia (CML) when supported by specific drugs. 

Read more